ArticleBMC cancer2025
Peripheral EBV antigen-specific T cell is dysfunctional in Epstein-Barr virus positive diffuse large B-cell lymphoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Assessing T-cell responses to Epstein-Barr virus in individuals at risk for nasopharyngeal carcinoma.Infectious agents and cancer · 2026Article
- Latent EBV reactivation drives aberrant B-cell proliferation during ex vivo tumor-infiltrating lymphocyte expansion from EBV-negative rectal cancer tumor tissue.Scientific reports · 2025Article
- Immunological profile and its clinical implications in pediatric infectious mononucleosis.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
EBV-positive diffuse large B-cell lymphoma (EBV + DLBCL) is associated with poor prognosis, possibly due to the capacity of EBV to dampen host anti-tumor immunity. Patients' peripheral EBV antigen-specific T lymphocytes may be functional deficiency. This study investigated the mechanisms underlying this deficiency by examining the phenotypes and function of peripheral T cells via ELISPOT and flow cytometry. 6 EBV + DLBCL patients, 54 EBV-negative DLBCL (EBV- DLBCL) patients, and 12 healthy controls were enrolled. We observed significantly reduced IFN-γ secreting T cells in EBV + patients upon EBV peptides stimulation compared to EBV-negative patients (P < 0.001), indicating a dysfunction in EBV antigen-specific T cells. Furtherly, compared to EBV- DLBCL, EBV + DLBCL showed decreased proportions of total lymphocytes (P = 0.005), CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.